✨ Free AI Report
BioVie Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview BioVie Inc.
Research Preview

BioVie Inc.: Business Overview, Financials & Competitive Analysis

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) a...

Analyst-debate audio for BioVie Inc.

AskCyborg analysts argue the bull and bear cases for BioVie Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
BioVie Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Clinical-stage nanocap with multi-disease bezisterim potential, but pre-revenue, heavily cash-constrained, and dependent on...

Read the full analyst-debate transcript →
Industry Biotechnology
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest BioVie Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

BioVie Inc. Overview

Pro stress-test →

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. The company's pipeline is built around two core assets: bezisterim (NE3107) targeting neuroinflammation, and BIV201 for advanced liver disease management.

Strategic Profile

Pro stress-test →

Its lead asset, bezisterim (NE3107), is a first-in-class, orally available small molecule that generated encouraging Phase 2 results in early Parkinson's disease, including statistically significant improvements across motor and non-motor measures, reductions in inflammatory biomarkers, and favorable changes in markers of neurodegeneration. The company plans to separate the BIV201 asset into Option Therapeutics, which is pursuing independent financing to advance BIV201 into Phase 3 while BioVie is expected to retain a majority ownership position.

Competitive Landscape

Pro stress-test →

BioVie competes in clinical-stage neurodegeneration and advanced liver disease spaces against larger biotech companies with established pipelines and superior capital positions. Direct competitors include Eli Lilly, Biogen, and Roche in Alzheimer's/Parkinson's development, and Intercept Pharmaceuticals and Gilead Sciences in liver disease. BioVie's differentiation hinges on bezisterim's first-in-class TNF-α inhibition mechanism and multi-indication optionality, though execution risk is elevated given nanocap scale and pre-revenue status.

Industry Context

BioVie Inc. operates in Biotechnology.

Key facts

Founded: 2013 · Headquarters: Carson City, Nevada, US · Employees: 13 · Revenue: $0 as of Q1 2026 · Market cap: $11.0M-$17.3M

What the analysts stress-tested

The top findings that survived the multi-agent debate for BioVie Inc..

+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when BioVie Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Eli LillyLarge-cap pharma with established Alzheimer's pipeline→BiogenBiotech focused on Alzheimer's and neuroinflammation→RocheLarge pharma with established CNS pipeline→Intercept PharmaceuticalsBiotech focused on liver disease and cholestatic disorders→

Compare BioVie Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BioVie Inc. operates in Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology research →
NEW · MCP server

Ask your AI assistant about BioVie Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BioVie Inc. and its top competitor on Cyborg Score”
“What did BioVie Inc. do this quarter?”
“Is BioVie Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does BioVie Inc. do?+
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) a...
What is BioVie Inc.'s Cyborg Score?+
BioVie Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BioVie Inc.'s main competitors?+
Named competitors include Eli Lilly, Biogen, Roche, Intercept Pharmaceuticals. The full competitive landscape is in the AskCyborg report.
How can I get the full BioVie Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BioVie Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BioVie Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend Biotech7Biogen Inc.8F. Hoffmann-La Roche AGTop companies in Biotechnology by Cyborg Score